A prospective PK study in 6 children aged 1.9 years to 8.3 years with micropenis found the following PK parameters after percutaneous administration of 0.15 to 0.33 mg/kg once daily [Charmandari 2001]:
| Tmax (hours) | 2-8 |
| Cmax (nmol/L) | 0.98-23.80 |
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
No information is present at this moment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
No information is present at this moment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
| Pre-operative for hypospadias |
|---|
|
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
No information available on dose adjustment in renal impairment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here
The following transient side effects were seen: itching, redness, penile skin darkening [Kaya 2008][Choi 1993], suppression of the pituitary-gonadal axis, decrease of serum sex hormone binding globulin, decrease in total cholesterol, HDL and HDL-total cholesterol ratios, increase of alkaline phosphatase [Choi 1993].
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here
No information available on specific contra indications in children.
The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here
Parents are recommended to wear gloves when applying the gel.
Monitoring during treatment should include regular pubertal assessment and measurement of DHT and testosterone concentrations on days 3 or 4 of treatment and prior to DHT gel application to ensure that the concentrations attained are not raised to a level that would be expected to result in the systemic effects described in association with percutaneous DHT treatment [Charmandari 2001].
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
| 3-oxoandrosten (4) derivatives | ||
|---|---|---|
| G03BA03 | ||
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.